Annual Accounts Payable
$22.37 B
+$19.82 B+777.41%
31 December 2023
Summary:
AstraZeneca annual accounts payable is currently $22.37 billion, with the most recent change of +$19.82 billion (+777.41%) on 31 December 2023. During the last 3 years, it has risen by +$20.02 billion (+852.09%). AZN annual accounts payable is now at all-time high.AZN Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$21.68 B
+$1.22 B+5.97%
30 September 2024
Summary:
AstraZeneca quarterly accounts payable is currently $21.68 billion, with the most recent change of +$1.22 billion (+5.97%) on 30 September 2024. Over the past year, it has increased by +$1.14 billion (+5.56%). AZN quarterly accounts payable is now at all-time high.AZN Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +777.4% | +5.6% |
| 3 y3 years | +852.1% | +16.2% |
| 5 y5 years | +1200.8% | +73.0% |
AZN Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +852.1% | at high | +750.4% |
| 5 y | 5 years | at high | +1200.8% | at high | +1122.3% |
| alltime | all time | at high | +4395.1% | at high | +3365.5% |
AstraZeneca Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $21.68 B(+6.0%) |
| June 2024 | - | $20.46 B(+3.9%) |
| Mar 2024 | - | $19.70 B(+503.0%) |
| Dec 2023 | $22.37 B(+777.4%) | $3.27 B(-84.1%) |
| Sept 2023 | - | $20.54 B(+4.1%) |
| June 2023 | - | $19.74 B(+2.7%) |
| Mar 2023 | - | $19.21 B(+653.3%) |
| Dec 2022 | $2.55 B(-9.7%) | $2.55 B(-85.6%) |
| Sept 2022 | - | $17.69 B(-0.7%) |
| June 2022 | - | $17.82 B(-0.2%) |
| Mar 2022 | - | $17.86 B(+532.6%) |
| Dec 2021 | $2.82 B(+20.2%) | $2.82 B(-84.9%) |
| Sept 2021 | - | $18.66 B(+5.3%) |
| June 2021 | - | $17.73 B(+2.1%) |
| Mar 2021 | - | $17.37 B(+639.1%) |
| Dec 2020 | $2.35 B(+32.5%) | $2.35 B(-82.5%) |
| Sept 2020 | - | $13.41 B(+11.5%) |
| June 2020 | - | $12.03 B(-4.8%) |
| Mar 2020 | - | $12.63 B(+612.1%) |
| Dec 2019 | $1.77 B(+3.1%) | $1.77 B(-85.9%) |
| Sept 2019 | - | $12.54 B(-0.8%) |
| June 2019 | - | $12.64 B(-3.5%) |
| Mar 2019 | - | $13.10 B(+661.7%) |
| Dec 2018 | $1.72 B(-24.7%) | $1.72 B(-84.4%) |
| Sept 2018 | - | $10.99 B(+0.7%) |
| June 2018 | - | $10.91 B(-4.9%) |
| Mar 2018 | - | $11.48 B(+402.5%) |
| Dec 2017 | $2.29 B(+36.0%) | $2.29 B(-78.9%) |
| Sept 2017 | - | $10.83 B(+7.5%) |
| June 2017 | - | $10.07 B(+1.7%) |
| Mar 2017 | - | $9.90 B(+489.2%) |
| Dec 2016 | $1.68 B(-51.6%) | $1.68 B(-83.1%) |
| Sept 2016 | - | $9.96 B(-2.9%) |
| June 2016 | - | $10.26 B(-8.2%) |
| Mar 2016 | - | $11.17 B(+222.1%) |
| Dec 2015 | $3.47 B(-0.7%) | $3.47 B(-67.3%) |
| Sept 2015 | - | $10.59 B(-0.6%) |
| June 2015 | - | $10.66 B(+1.4%) |
| Mar 2015 | - | $10.51 B(+201.0%) |
| Dec 2014 | $3.49 B(+39.7%) | $3.49 B(-65.6%) |
| Sept 2014 | - | $10.15 B(-1.5%) |
| June 2014 | - | $10.30 B(-3.0%) |
| Mar 2014 | - | $10.63 B(+325.2%) |
| Dec 2013 | $2.50 B(+2.0%) | $2.50 B(-73.0%) |
| Sept 2013 | - | $9.24 B(-4.1%) |
| June 2013 | - | $9.64 B(+1.9%) |
| Mar 2013 | - | $9.46 B(+286.5%) |
| Dec 2012 | $2.45 B | $2.45 B(-71.6%) |
| Sept 2012 | - | $8.63 B(-3.8%) |
| June 2012 | - | $8.97 B(+0.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $8.95 B(-0.3%) |
| Dec 2011 | $8.97 B(+297.7%) | $8.97 B(+11.8%) |
| Sept 2011 | - | $8.03 B(-5.7%) |
| June 2011 | - | $8.51 B(-1.8%) |
| Mar 2011 | - | $8.67 B(+284.2%) |
| Dec 2010 | $2.26 B(-15.1%) | $2.26 B(-71.0%) |
| Sept 2010 | - | $7.80 B(+5.9%) |
| June 2010 | - | $7.36 B(-13.5%) |
| Mar 2010 | - | $8.51 B(+220.1%) |
| Dec 2009 | $2.66 B(-63.0%) | $2.66 B(-64.0%) |
| Sept 2009 | - | $7.38 B(+0.3%) |
| June 2009 | - | $7.37 B(+3.0%) |
| Mar 2009 | - | $7.15 B(-0.4%) |
| Dec 2008 | $7.18 B(+105.3%) | $7.18 B(+3.4%) |
| Sept 2008 | - | $6.94 B(-6.3%) |
| June 2008 | - | $7.41 B(+3.0%) |
| Mar 2008 | - | $7.19 B(+105.7%) |
| Dec 2007 | $3.50 B(+0.4%) | $3.50 B(-47.3%) |
| Sept 2007 | - | $6.63 B(-5.6%) |
| June 2007 | - | $7.03 B(+1.6%) |
| Mar 2007 | - | $6.91 B(+98.5%) |
| Dec 2006 | $3.48 B(-36.3%) | $3.48 B(-39.8%) |
| Sept 2006 | - | $5.78 B(-12.1%) |
| June 2006 | - | $6.57 B(+3.8%) |
| Mar 2006 | - | $6.33 B(+15.9%) |
| Dec 2005 | $5.47 B(+74.9%) | $5.47 B(+1.1%) |
| Sept 2005 | - | $5.40 B(-1.7%) |
| June 2005 | - | $5.50 B(+0.5%) |
| Mar 2005 | - | $5.47 B(+74.9%) |
| Dec 2004 | $3.13 B(+1.3%) | $3.13 B(-52.6%) |
| Sept 2004 | - | $6.59 B(-14.1%) |
| Mar 2004 | - | $7.67 B(+148.7%) |
| Dec 2003 | $3.09 B(-2.7%) | $3.09 B(-2.7%) |
| Dec 2002 | $3.17 B(+33.0%) | $3.17 B(-54.0%) |
| Sept 2002 | - | $6.90 B(+189.3%) |
| Dec 2001 | $2.38 B(-20.6%) | $2.38 B(-62.8%) |
| Sept 2001 | - | $6.40 B(+113.1%) |
| Dec 2000 | $3.01 B(+86.2%) | $3.01 B(-58.4%) |
| Sept 2000 | - | $7.22 B(+347.5%) |
| Dec 1999 | $1.61 B(+84.6%) | $1.61 B(-40.7%) |
| June 1998 | - | $2.72 B(+211.5%) |
| Dec 1997 | $874.50 M(+6.6%) | $874.50 M(+6.6%) |
| Dec 1996 | $820.29 M(-0.2%) | $820.29 M(-0.2%) |
| Dec 1995 | $822.05 M(+3.9%) | $822.05 M(-67.9%) |
| June 1995 | - | $2.56 B(+224.1%) |
| Dec 1994 | $791.08 M(+26.4%) | $791.08 M(+26.4%) |
| Dec 1993 | $625.70 M(+17.9%) | $625.70 M |
| Dec 1992 | $530.84 M(+6.7%) | - |
| Dec 1991 | $497.74 M(-65.4%) | - |
| Dec 1990 | $1.44 B | - |
FAQ
- What is AstraZeneca annual accounts payable?
- What is the all time high annual accounts payable for AstraZeneca?
- What is AstraZeneca annual accounts payable year-on-year change?
- What is AstraZeneca quarterly accounts payable?
- What is the all time high quarterly accounts payable for AstraZeneca?
- What is AstraZeneca quarterly accounts payable year-on-year change?
What is AstraZeneca annual accounts payable?
The current annual accounts payable of AZN is $22.37 B
What is the all time high annual accounts payable for AstraZeneca?
AstraZeneca all-time high annual accounts payable is $22.37 B
What is AstraZeneca annual accounts payable year-on-year change?
Over the past year, AZN annual accounts payable has changed by +$19.82 B (+777.41%)
What is AstraZeneca quarterly accounts payable?
The current quarterly accounts payable of AZN is $21.68 B
What is the all time high quarterly accounts payable for AstraZeneca?
AstraZeneca all-time high quarterly accounts payable is $21.68 B
What is AstraZeneca quarterly accounts payable year-on-year change?
Over the past year, AZN quarterly accounts payable has changed by +$1.14 B (+5.56%)